期刊文献+

Excision repair cross complementation group 1 polymorphisms and lung cancer risk: a meta-analysis 被引量:9

Excision repair cross complementation group 1 polymorphisms and lung cancer risk: a meta-analysis
原文传递
导出
摘要 Background Several studies have evaluated the association between polymorphisms of encoding excision repair cross complementation group 1 (ERCC1) enzyme and lung cancer risk in diverse populations but with conflicting results.By pooling the relatively small samples in each study, it is possible to perform a meta-analysis of the evidence by rigorous methods.Methods Embase, Ovid, Medline and Chinese National Knowledge Infrastructure were searched. Additional studies were identified from references in original studies or review articles. Articles meeting the inclusion criteria were reviewed systematically, and the reported data were aggregated using the statistical techniques of meta-analysis.Results We found 3810 cases with lung cancer and 4332 controls from seven eligible studies. T19007C polymorphism showed no significant effect on lung cancer risk (C allele vs. T allele: odds ratio (OR)=0.91, 95% confidence interval (CI)=0.80-1.04; CC vs. TT: OR=0.76, 95% CI=0.56-1.02; CC vs. (CT+TT): OR=0.96, 95% CI=-0.84-1.10). Similarly,there was no significant main effects for T19007C polymorphism on lung cancer risk when stratified analyses by ethnicity (Chinese or Caucasian). No significant association was found between C8092A polymorphism (3060 patients and 2729 controls) and the risk of lung cancer (A allele vs. C allele: OR=1.03, 95% CI=0.95-1.11; AA vs. CC: OR=1.08, 95% CI=-0.88-1.33; AA vs. (AC+CC): OR=1.08, 95% CI=-0.88-1.31).Conclusion We found little evidence of an association between the T1900C or C8092A polymorphisms of ERCC 1 and the risk of lung cancer in Caucasian or Han Chinese people. Background Several studies have evaluated the association between polymorphisms of encoding excision repair cross complementation group 1 (ERCC1) enzyme and lung cancer risk in diverse populations but with conflicting results.By pooling the relatively small samples in each study, it is possible to perform a meta-analysis of the evidence by rigorous methods.Methods Embase, Ovid, Medline and Chinese National Knowledge Infrastructure were searched. Additional studies were identified from references in original studies or review articles. Articles meeting the inclusion criteria were reviewed systematically, and the reported data were aggregated using the statistical techniques of meta-analysis.Results We found 3810 cases with lung cancer and 4332 controls from seven eligible studies. T19007C polymorphism showed no significant effect on lung cancer risk (C allele vs. T allele: odds ratio (OR)=0.91, 95% confidence interval (CI)=0.80-1.04; CC vs. TT: OR=0.76, 95% CI=0.56-1.02; CC vs. (CT+TT): OR=0.96, 95% CI=-0.84-1.10). Similarly,there was no significant main effects for T19007C polymorphism on lung cancer risk when stratified analyses by ethnicity (Chinese or Caucasian). No significant association was found between C8092A polymorphism (3060 patients and 2729 controls) and the risk of lung cancer (A allele vs. C allele: OR=1.03, 95% CI=0.95-1.11; AA vs. CC: OR=1.08, 95% CI=-0.88-1.33; AA vs. (AC+CC): OR=1.08, 95% CI=-0.88-1.31).Conclusion We found little evidence of an association between the T1900C or C8092A polymorphisms of ERCC 1 and the risk of lung cancer in Caucasian or Han Chinese people.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2011年第14期2203-2208,共6页 中华医学杂志(英文版)
关键词 excision repair cross complementation group 1 POLYMORPHISM lung cancer SUSCEPTIBILITY META-ANALYSIS excision repair cross complementation group 1 polymorphism lung cancer susceptibility meta-analysis
  • 相关文献

参考文献4

二级参考文献28

  • 1Stinchcombe TE,Socinski MA.Considerations for second-line therapy of non-small cell lung cancer.Oncologist 2008; 13:28-36.
  • 2Cohen MH,Johnson JR,Wang YC,Sddhara R,Pazdur R.FDA drug approval summary:Pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer.Oncologist 2005; 10:363-368.
  • 3Hanna N,Shepherd FA,Fossella FV,Pereira JR,De Marinis F,yon Pawel J,et al.Randomized phase Ⅲ trial of pemetrexed versus docetaxei in patients with non-small-cell lung cancer previously treated with chemotherapy.J Clin Oncol 2004; 22:1589-1597.
  • 4Kim YH,Kim JS,Choi YH,In KH,Park HS,Hong DS,et al.Phase Ⅱ study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer,Int J Clin Oncol 2002; 7:114-119.
  • 5D'Addario G,Pintilie M,Leighl NB,Feld R,Cerny T,Shepherd FA.Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer:a recta-analysis of the published literature.J Clin Oncol 2005;23:2926-2936.
  • 6Wakelee H,Belani CP.Optimizing first-line treatment options for patients with advanced NSCLC.Oncologist 2005; 10 Suppl 3:1-10.
  • 7Ohe Y,lchinose Y,Nakagawa K,Tamura T,Kubota K,Yamamoto N,et al.Efficacy and safety of two doses of pemetrexed supplemented with folio acid and vitamin B12 in previously treated patients with non-small cell lung cancer.Clin Cancer Res 2008; 14:4206-4212.
  • 8Molina JR,Adjei AA.The role of Pemetrexed (Alimta,LY231514) in lung cancer therapy.Clin Lung Cancer 2003; 5:21-27.
  • 9Shepherd FA,Dancey J,Arnold A,Neville A,Rusthoven J,Johnson RD,et al.Phase Ⅱ study of pemetrexed disodium,a multitargeted antifolate,and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma.Cancer 2001; 92:595-600.
  • 10Weiss GJ,Langer C,Rosell R,Hanna N,Shepherd F,Einhom LH,et al.Elderly patients benefit from second-line cytotoxic chemotherapy:a subset analysis of a randomized phase Ⅲ trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.J Clin Oncol 2006; 24:4405-4411.

共引文献40

同被引文献17

引证文献9

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部